Drugs / Yttrium-90 Glass Microspheres
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05016245 | Sep 2021 → Feb 2026 overdue | hepatocellular carcinoma | Boston Scientific Corporation | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2021-09-20 | Boston Scientific Corporation | Results Late-Breaking Data Demonstrate Improved Progression-Free Survival in Patients with Metastatic Colorectal Cancer After Treatment with Boston Scientific TheraSphere™ Y-90 Glass Microspheres bostonscientific.com ↗
The clinical findings were presented today as late-breaking data at the European Society for Medical Oncology (ESMO) Congress 2021 and will be published in the Journal of Clinical Oncology . |
| 2021-03-25 | Boston Scientific Corporation | Results Late-Breaking Clinical Trial Data for TheraSphere™ Y-90 Glass Microspheres Demonstrates Improved Survival in Primary Liver Cancer bostonscientific.com ↗
Data confirmed treatment was safe and well tolerated, with only 4.8% of patients experiencing adverse events, defined in the primary endpoint as ≥ Grade 3 hyperbilirubinemia. |
| 2021-03-18 | Boston Scientific Corporation | Regulatory Boston Scientific Receives FDA Approval for TheraSphere™ Y-90 Glass Microspheres bostonscientific.com ↗
Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere™ Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma (HCC). |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-09-20 | Boston Scientific Corporation | Late-Breaking Data Demonstrate Improved Progression-Free Survival in Patients with Metastatic Colorectal Cancer After Treatment with Boston Scientific TheraSphere™ Y-90 Glass Microspheres bostonscientific.com ↗ |
| 2021-03-25 | Boston Scientific Corporation | Late-Breaking Clinical Trial Data for TheraSphere™ Y-90 Glass Microspheres Demonstrates Improved Survival in Primary Liver Cancer bostonscientific.com ↗ |
| 2021-03-18 | Boston Scientific Corporation | Boston Scientific Receives FDA Approval for TheraSphere™ Y-90 Glass Microspheres bostonscientific.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Yttrium-90 Glass Microspheres | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05016245 ↗ |
| Known as | TheraSphere | “TheraSphere™ Yttrium-90 Glass Microspheres TheraSphere™ is steam sterilized and supplied in 6 standard dose sizes: 3 GBq, 5 GBq, 7 GBq, 10 GBq, 15 GBq, 20 GBq.” NCT05016245 ↗ |